Eli Lilly and Company
The brain is one of the most complex – and most fascinating – organs in the human body, and one that can be impacted by countless diseases and disorders.
A neuroscientist and neuropathologist by training, Dan is responsible for development across all of Lilly's products - from clinical trials through approvals - specifically working within the areas of oncology, diabetes, Alzheimer's disease, immunology and pain management.
America's biopharmaceutical companies are at the heart of a robust research and development (R&D) ecosystem that supports continued medical advances for patients.
<p>The evolution of HIV/AIDS treatment is nothing short of remarkable. In the 1980s, HIV/AIDS was an acute fatal disease. Today it is a chronic, manageable condition thanks to the commitment of biopharmaceutical researchers, health care workers and advocates.</p>READ MORE
<p><span><span><span><a><span lang="EN"><span>America's biopharmaceutical companies are researching and developing new treatments to alleviate the tremendous burden of this devastating and painful disease and to improve the quality of life for sickle cell patients.</span></span></a></span></span></span></p>READ MORE
<p>Why, when we have seen such progress in our ability to treat other diseases, such as cancer, diabetes and HIV, has progress in Alzheimer's research been so difficult to achieve?</p>READ MORE